MA55801A - Formes solides d'un inhibiteur de glyt1 - Google Patents
Formes solides d'un inhibiteur de glyt1Info
- Publication number
- MA55801A MA55801A MA055801A MA55801A MA55801A MA 55801 A MA55801 A MA 55801A MA 055801 A MA055801 A MA 055801A MA 55801 A MA55801 A MA 55801A MA 55801 A MA55801 A MA 55801A
- Authority
- MA
- Morocco
- Prior art keywords
- solid forms
- glyt1 inhibitor
- glyt1
- inhibitor
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55801A true MA55801A (fr) | 2022-03-09 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055801A MA55801A (fr) | 2019-05-01 | 2020-04-30 | Formes solides d'un inhibiteur de glyt1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (fr) |
| EP (1) | EP3962911A1 (fr) |
| JP (2) | JP7513349B2 (fr) |
| KR (1) | KR20220004174A (fr) |
| CN (1) | CN113784966B (fr) |
| AR (1) | AR118839A1 (fr) |
| AU (1) | AU2020266566A1 (fr) |
| BR (1) | BR112021020883A2 (fr) |
| CA (1) | CA3138288A1 (fr) |
| CL (1) | CL2021002837A1 (fr) |
| CO (1) | CO2021014260A2 (fr) |
| CR (1) | CR20210545A (fr) |
| DO (1) | DOP2021000224A (fr) |
| EA (1) | EA202192925A1 (fr) |
| EC (1) | ECSP21082195A (fr) |
| IL (1) | IL287630A (fr) |
| JO (1) | JOP20210295A1 (fr) |
| MA (1) | MA55801A (fr) |
| MX (1) | MX2021013341A (fr) |
| PE (1) | PE20212263A1 (fr) |
| SG (1) | SG11202111972YA (fr) |
| TW (1) | TW202106680A (fr) |
| WO (1) | WO2020223419A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| CN116212025A (zh) | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| MX2023001818A (es) | 2020-08-13 | 2023-03-13 | Boehringer Ingelheim Int | Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia. |
| CN117567449A (zh) | 2020-10-13 | 2024-02-20 | 勃林格殷格翰国际有限公司 | 再加工方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| MXPA06004279A (es) * | 2003-10-14 | 2006-06-28 | Pfizer Prod Inc | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina. |
| AU2009322420A1 (en) * | 2008-12-04 | 2011-06-23 | Sanofi | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| CN102271677A (zh) * | 2008-12-29 | 2011-12-07 | 凡德贝尔大学 | 3.1.0双环G1yT1抑制剂及其制备和使用方法 |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| US10919891B2 (en) | 2017-04-27 | 2021-02-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2020
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/fr active Pending
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/fr active Application Filing
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/fr active Pending
- 2020-04-30 AU AU2020266566A patent/AU2020266566A1/en active Pending
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en active Pending
-
2024
- 2024-05-02 JP JP2024074707A patent/JP2024100792A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004174A (ko) | 2022-01-11 |
| CN113784966A (zh) | 2021-12-10 |
| ECSP21082195A (es) | 2021-12-30 |
| AU2020266566A1 (en) | 2021-11-11 |
| JP2024100792A (ja) | 2024-07-26 |
| CN113784966B (zh) | 2024-07-19 |
| US11447474B2 (en) | 2022-09-20 |
| US20200347041A1 (en) | 2020-11-05 |
| JOP20210295A1 (ar) | 2023-01-30 |
| CA3138288A1 (fr) | 2020-11-05 |
| PE20212263A1 (es) | 2021-11-29 |
| MX2021013341A (es) | 2021-11-17 |
| TW202106680A (zh) | 2021-02-16 |
| CR20210545A (es) | 2021-12-23 |
| SG11202111972YA (en) | 2021-11-29 |
| US20220332710A1 (en) | 2022-10-20 |
| CL2021002837A1 (es) | 2022-07-29 |
| WO2020223419A1 (fr) | 2020-11-05 |
| JP7513349B2 (ja) | 2024-07-09 |
| EA202192925A1 (ru) | 2022-03-23 |
| JP2022530630A (ja) | 2022-06-30 |
| EP3962911A1 (fr) | 2022-03-09 |
| AR118839A1 (es) | 2021-11-03 |
| CO2021014260A2 (es) | 2021-10-29 |
| DOP2021000224A (fr) | 2021-12-15 |
| IL287630A (en) | 2021-12-01 |
| BR112021020883A2 (pt) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| DK3880670T3 (da) | Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse | |
| MA41252A (fr) | Formes solides d'un inhibiteur d'ask 1 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA41827A (fr) | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| MA54901A (fr) | Inhibiteur de 15-pgdh | |
| MA45588A (fr) | Formes solides d'un stimulateur de la gcs | |
| MA53010A (fr) | Formulations d'un inhibiteur de axl/mer | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
| MA53635A (fr) | Utilisation d'un inhibiteur de la cathepsine s contre la formation d'anticorps anti-médicament | |
| MA53546A (fr) | Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide | |
| MA54856A (fr) | Monohydrate de chlorhydrate de rogaratinib et états solides associés | |
| MA53561A (fr) | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) | |
| MA45691A (fr) | Formes solides d'inhibiteur de ttk | |
| MA45393A (fr) | Formes cristallines solides d'un inhibiteur bet | |
| ES2980695T3 (es) | Profármaco de inhibidor de caspasas |